Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ERN1 | O75460 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | TACR2 | P21452 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16341832 | 0.83 | ERN1 (0.38) | LMNAHPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL7704423 | 0.77 | ALDH1A1 (0.44) | LMNAHPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL18374938 | 0.77 | LMNA (0.52) | LMNAHPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL13812603 | 0.75 | ALDH1A1 (0.43) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL18364556 | 0.75 | LMNA (0.40) | LMNAALDH1A1KDM4EERN1TSHR | |
| SCHEMBL24167762 | 0.74 | AR (0.43) | LMNAHPGDSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL17788087 | 0.71 | HPGD (0.44) | LMNAHPGDSMN1; SMN2POLBKDM4E | |
| SCHEMBL3599860 | 0.71 | ERN1 (0.68) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL10019788 | 0.71 | LMNA (0.51) | LMNAHPGDSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL6901385 | 0.71 | LMNA (0.46) | LMNAHPGDALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994509-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | HIVIH (FR) | 2018-06-12 | — | — | US | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-06-02 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160152543-A1 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | POLRMT, MAVS, EIF2AK2 | LMNA 1686/4885HPGD 2452/4885SMN1; SMN2 3115/4885 |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, MAVS | LMNA 1718/4885HPGD 2006/4885SMN1; SMN2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.